INCY Incyte Corporation
Nasdaq · Health Care · Services-Commercial Physical & Biological Research · Market cap $23.8B · $115.30 on 2026-10-02
On deckTier CDetailed (TTM)
Price moves
1 week-7%
1 month-9%
3 months-1%
6 months20%
YTD8%
1 year33%
Off 52w high-13%
52w range$83–$133
Price history
Show year-end values
| Year | Price |
|---|---|
| 2016 | $100.27 |
| 2017 | $94.71 |
| 2018 | $63.59 |
| 2019 | $87.32 |
| 2020 | $86.98 |
| 2021 | $73.40 |
| 2022 | $80.32 |
| 2023 | $62.79 |
| 2024 | $69.07 |
| 2025 | $98.77 |
| 2026-10-02 (latest) | $115.30 |
Ten Cap
$70
$70
Buy (MOS)
$102
$102
Payback Time
$110
$110
Sticker
$205
$205
Price
$115
$115
Valuation
| Buy (MOS) 50% of Sticker | $102.34 | -11% |
|---|---|---|
| Ten Cap 10× owner earnings | $69.57 | -40% |
| Payback Time 8-year FCF payback | $109.82 | -5% |
| Sticker Rule #1 intrinsic value | $204.69 | 78% |
| Windage growth g | 15.0% | |
| Future P/E (min 2g, 10y median) | 28.9× | |
| P/E · 10y median | 16.3× | 28.9× |
| EPS TTM 2026-03-31 | $7.08 | |
| FCF yield | 6.0% | |
| Dividend (TTM) · yield | – | – |
| Total return per year, dividends reinvested · 5y · 10y | 10.7% | 1.2% |
| Revenue · net income last FY | $5.1B | $1.3B |
Big Five 12/15 tests ≥10%
| 10y | 5y | 1y | |
|---|---|---|---|
| ROIC | 6% | 11% | 23% |
| Sales growth | 21% | 14% | 21% |
| EPS growth | 71% | – | 4173% |
| BVPS growth | 40% | 17% | 57% |
| OCF growth | 32% | – | 322% |
| Debt payoff (yrs of FCF) | 0.0 |
Events
13D: SCHEDULE 13D/A 2026-05-11; 8-K: 2026-08-31: 8.01 Other event; next report ~2026-10-27
Next report ≈ 2026-10-27 · SEC filings ·Yahoo Finance